A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Key claim: A randomized placebo-controlled trial is evaluating whether elritercept improves anemia, fatigue, MF symptoms, and physical function in myelofibrosis patients already receiving ruxolitinib.
Abstract
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo.
Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness, improves symptoms related to MF, and helps participants do physical activities more easily. The study also aims to find out how elritercept affects the bone marrow, the spleen, and whether participants develop antibodies to the study drug.
The study will also check how safe elritercept is compared to placebo, and if elritercept stays safe over a long period of time. Participants will receive study treatment for at least 9 months (36 weeks). After this period, participants who received placebo will have the option to switch to elritercept.
Why this matters
Elritercept advancing into a randomized placebo-controlled trial marks the maturation of activin/TGF-β ligand trap therapy as a candidate add-on for ruxolitinib-treated MF patients whose anemia drives persistent fatigue. Because the trial co-evaluates anemia, fatigue, MF symptom burden, and physical function, it will help disentangle whether correcting anemia in this setting yields measurable patient-reported symptom benefit — a question repeatedly raised by the spleen–symptom dissociation seen in other MF combination trials.